S-Kinase 1.5 million unit (Powder for Injection)
1.5 million unit vial: ৳ 4,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Streptokinase |
| Company | Popular pharmaceuticals ltd |
Indications
- Management of acute myocardial infarction
- Lysis of intracoronary thrombi
- Improvement of ventricular function
- Reduction of mortality
- Administration by intravenous or intracoronary route
Pharmacology
- Formation of complex with plasminogen
- Conversion of plasminogen to plasmin
- Clot breakdown
- Fibrinogen breakdown
Dosage & Administration
- Reconstitution with sodium chloride injection or 5% dextrose injection
- Intravenous infusion details
- Intracoronary infusion details
- Dosage for pulmonary embolism, deep vein thrombosis, arterial thrombosis or embolism
Interaction
- Increased risk of hemorrhage
- Interaction with anticoagulants
- Combination with aspirin for treatment of myocardial infarction
- Concomitant use of acetylsalicylic acid (aspirin)
- Anticoagulation treatment following S-Kinase
Contraindications
- Risk of bleeding
- Internal bleeding potential
- Recent cerebrovascular accident
- Recent facial or head trauma
- Intracranial or intraspinal surgery
- Invasive operations
- Arteriovenous malformation or aneurysm
- Severe uncontrolled hypertension
- Severe liver or kidney damage
- Endocarditis or pericarditis
- More than 5 days and less than 12 months since previous Streptokinase therapy
Side Effects
- Headache
- Back pain
- Muscle pain
- Chills and/or fever
- Asthenia/malaise
- Haemorrhages at invaded or disturbed sites
- Gastrointestinal or genitourinary bleeding
- Immune system development of antiS-Kinase antibodies
- Allergic-anaphylactic reactions
- Neurologic symptoms
- Hypotension
- Heart rate and rhythm disorders
- Recurrent ischemia
- Nausea
- Diarrhea
- Epigastric pain
Pregnancy & Lactation
- Pregnancy category C
- Potential excretion in breast milk
- Recommendation to discontinue breastfeeding
Precautions & Warnings
- Increased likelihood of resistance due to antiS-Kinase antibodies
- No thrombolytic treatment before the 10th postoperative day
- Danger of bleeding from operative area
- Increased danger of hemorrhage with simultaneous or previous anticoagulant treatment
- Danger of resistance to S-Kinase during elevated antiS-Kinase antibody titre
Use in Special Populations
- Safety & effectiveness not established for pediatric use
Overdose Effects
- Uncontrollable bleeding
- Immediate cessation of S-Kinase infusion
- Reversible bleeding with appropriate replacement therapy
- Possible use of aminocaproic acid or aprotinin
Therapeutic Class
- Fibrinolytics (Thrombolytics)
Reconstitution
- Careful reconstitution and dilution required
- Reconstitution and dilution procedures for vials & infusion bottles
- Visual inspection for particulate matter and discoloration prior to administration
- No addition of other medication to the container
- Discard of unused reconstituted drug
Storage Conditions
- Storage temperature for S-Kinase vial
- Physico-chemical stability after reconstitution
- Microbiological point of view for reconstituted product
- Storage duration for reconstituted product
- Keep out of the reach of children